Finance

Lists
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
$ 8.83
+0.17%
(+0.015) 1D
10-р сарын 14, 14:30:40 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SGIOY...
Open
$ 8.86
High
$ 8.86
Low
$ 8.72
Mkt. cap
2.48ИН
Avg. vol.
170.95 мян
Volume
58.94 мян
52-wk high
$ 12.00
52-wk low
$ 7.83
Beta
0.07
Shares outstanding
1.78 тэрбум
No. of employees
6 мян
Open
$ 8.86
High
$ 8.86
Low
$ 8.72
Mkt. cap
2.48ИН
Avg. vol.
170.95 мян
Volume
58.94 мян
52-wk high
$ 12.00
52-wk low
$ 7.83
Beta
0.07
Shares outstanding
1.78 тэрбум
No. of employees
6 мян
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
4 цагийн өмнө
SGIOY or UTHR: Which Is the Better Value Stock Right Now?
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6.22 мян
Founded1878
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
113.18Т
147.72Т
138.99Т
163.31Т
Cost of goods sold
16.94 тэрбум
25.09 тэрбум
28.10 тэрбум
30.80 тэрбум
Cost of revenue
16.94 тэрбум
25.09 тэрбум
28.10 тэрбум
30.80 тэрбум
Research and development expenses
27.55 тэрбум
29.87 тэрбум
40.54 тэрбум
31.79 тэрбум
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.56 тэрбум
35.27 тэрбум
32.92 тэрбум
44.36 тэрбум
Operating expense
56.57 тэрбум
48.45 тэрбум
100.06Т
113.87Т
Total operating expenses
73.51 тэрбум
73.54 тэрбум
128.17Т
144.66Т
Operating income
39.67 тэрбум
74.18 тэрбум
10.83 тэрбум
18.64 тэрбум
Other non operating income
-
-1.00 сая
7.31 тэрбум
-2.00 сая
EBT including unusual items
52.06 тэрбум
92.89 тэрбум
47.64 тэрбум
73.74 тэрбум
EBT excluding unusual items
52.06 тэрбум
93.10 тэрбум
47.80 тэрбум
25.47 тэрбум
Income tax expense
7.87 тэрбум
18.21 тэрбум
-56.00 сая
-23.98 тэрбум
Effective tax rate
15.12%
19.60%
-0.12%
-32.52%
Other operating expenses
979.00 сая
-17.25 тэрбум
15.44 тэрбум
21.90 тэрбум
Net income
44.19 тэрбум
74.68 тэрбум
46.93 тэрбум
97.70 тэрбум
Net profit margin
39.04%
50.56%
33.77%
59.82%
Earnings per share
-
-
-
-
Interest and investment income
14.21 тэрбум
20.53 тэрбум
23.73 тэрбум
12.15 тэрбум
Interest expense
-1.82 тэрбум
-1.61 тэрбум
-
-5.32 тэрбум
Net interest expenses
12.38 тэрбум
18.92 тэрбум
23.73 тэрбум
6.82 тэрбум
Depreciation and amortization charges
-485.00 сая
-
-1.53 тэрбум
-
EBITDA
44.83 тэрбум
80.21 тэрбум
21.59 тэрбум
39.52 тэрбум
Gain or loss from assets sale
-
-
35.04 тэрбум
-
AI content may include mistakes. Learn more
Google аппс